

Solomon Isl Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Solomon Isl						
2. Grant number: 1520-SLB-12c-X / /						
3. Date of Decision Letter: 16 December 2016						
4. Date of the Partnership Framework Agreement: 29 April 2013						
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine						
6. Vaccine type: Pneumococcal						
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID						
8. Programme duration¹: 2015 -2020						
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2015-2016	2017	2018	2019	2020	Total ²
Programme Budget (US\$)	507,000 ³	156,000	131,500	118,000	100,000	1,012,500
10. Vaccine introduction grant (in US\$): Not applicable						
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴						
Type of supplies to be purchased with Gavi funds in each year	2015-2016		2017			
Number of Pneumococcal vaccines doses			40,300			
Annual Amounts (US\$)	US\$507,000 ⁵		US\$156,000			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
13. Self-procurement: Not applicable						

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 1520-SLB-12c-X-C

According to the co-financing policy, the Country falls within the group Accelerated transition phase.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017	2018	2019	2020
Number of vaccine doses	17,700	25,200	34,100	42,800
Number of AD syringes	18,600			
Number of re-constitution syringes				
Number of safety boxes	225			
Value of vaccine doses (US\$)	58,300			
Total co-financing payments (US\$) (including freight)	62,500	88,500	120,000	150,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

Financial clarifications: Not applicable

17. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

16 December 2016